Dermatologic Manifestations of Glucagonoma Syndrome Differential Diagnoses

1. Vinik A, Feliberti E, Perry RR, De Groot LJ, Beck-Peccoz P, Chrousos G, et al. Glucagonoma Syndrome. 2000. [QxMD MEDLINE Link]. [Full Text].

2. Cardoso Filho Fde A, Feitosa RG, Fechine CO, de Matos CM, Cardoso AL, Cardoso DL. Glucagonoma syndrome associated with necrolytic migratory erythema. Rev Assoc Med Bras. 2015 May-Jun. 61 (3):203-6. [QxMD MEDLINE Link].

3. Aragón-Miguel R, Prieto-Barrios M, Calleja-Algarra A, Pinilla-Martin B, Rodriguez-Peralto J, Ortiz-Romero P, et al. Image Gallery: Necrolytic migratory erythema associated with glucagonoma. Br J Dermatol. 2019 Jan. 180 (1):e1. [QxMD MEDLINE Link].

4. Sandhu S, Jialal I. Glucagonoma Syndrome. StatPearls [Internet]. 2021 Jan. [QxMD MEDLINE Link]. [Full Text].

5. Foss MG, Ferrer-Bruker SJ. Necrolytic Migratory Erythema. StatPearls [Internet]. 2021 Jan. [QxMD MEDLINE Link]. [Full Text].

6. Nakashima H, Komine M, Sasaki K, Mitsui H, Fujimoto M, Ihn H, et al. Necrolytic migratory erythema without glucagonoma in a patient with short bowel syndrome. J Dermatol. 2006 Aug. 33(8):557-62. [QxMD MEDLINE Link].

7. Doyle JA, Schroeter AL, Rogers RS 3rd. Hyperglucagonaemia and necrolytic migratory erythema in cirrhosis--possible pseudoglucagonoma syndrome. Br J Dermatol. 1979 Nov. 101(5):581-7. [QxMD MEDLINE Link].

8. Echenique-Elizondo M, Tuneu Valls A, Elorza Orúe JL, Martinez de Lizarduy I, Ibáñez Aguirre J. Glucagonoma and pseudoglucagonoma syndrome. JOP. 2004 Jul. 5(4):179-85. [QxMD MEDLINE Link].

9. Coughlin CC, Roy SM, Arkin LM, Adzick NS, Yan AC, De León DD, et al. Iatrogenic Necrolytic Migratory Erythema in an Infant with Congenital Hyperinsulinism. Pediatr Dermatol. 2016 Mar. 33 (2):e43-e47. [QxMD MEDLINE Link].

10. Stavropoulos PG, Papafragkaki DK, Avgerinou G, Papafragkakis H, Katsavou A, Katsambas AD. Necrolytic migratory erythema: a common cutaneous clue of uncommon syndromes. Cutis. 2013 Nov. 92 (5):E1-4. [QxMD MEDLINE Link].

11. Luber AJ, Ackerman LS, Culpepper KS, Buschmann CM, Koep LJ. Pediatric Necrolytic Migratory Erythema as a Presenting Sign of Glucagonoma Syndrome. Br J Dermatol. 2015 Nov 20. [QxMD MEDLINE Link].

12. Fang S, Li S, Cai T. Glucagonoma syndrome: a case report with focus on skin disorders. Onco Targets Ther. 2014. 7:1449-53. [QxMD MEDLINE Link].

13. Sandhu S, Jialal I. Glucagonoma Syndrome. StatPearls. 2018 Jan. [QxMD MEDLINE Link]. [Full Text].

14. Chao SC, Lee JY. Brittle nails and dyspareunia as first clues to recurrences of malignant glucagonoma. Br J Dermatol. 2002 Jun. 146(6):1071-4. [QxMD MEDLINE Link].

15. Lewis RB, Lattin GE Jr, Paal E. Pancreatic endocrine tumors: radiologic-clinicopathologic correlation. Radiographics. 2010 Oct. 30(6):1445-64. [QxMD MEDLINE Link].

16. Lv WF, Han JK, Liu X, Wang SC, Pan BO, Xu AO. Imaging features of glucagonoma syndrome: A case report and review of the literature. Oncol Lett. 2015 Apr. 9 (4):1579-1582. [QxMD MEDLINE Link].

17. van der Loos TL, Lambrecht ER, Lambers JC. Successful treatment of glucagonoma-related necrolytic migratory erythema with dacarbazine. J Am Acad Dermatol. 1987 Feb. 16(2 Pt 2):468-72. [QxMD MEDLINE Link].

18. Nitta N, Ohta S, Tanaka T, Takazakura R, Toyama T, Sonoda A, et al. An initial clinical study on the efficacy of cisplatin-releasing gelatin microspheres for metastatic liver tumors. Eur J Radiol. 2009 Sep. 71(3):519-26. [QxMD MEDLINE Link].

19. Melen-Mucha G, Lawnicka H, Kierszniewska-Stepien D, Komorowski J, Stepien H. The place of somatostatin analogs in the diagnosis and treatment of the neuoroendocrine glands tumors. Recent Pat Anticancer Drug Discov. 2006 Jun. 1(2):237-54. [QxMD MEDLINE Link].

20. Eldor R, Glaser B, Fraenkel M, Doviner V, Salmon A, Gross DJ. Glucagonoma and the glucagonoma syndrome - cumulative experience with an elusive endocrine tumour. Clin Endocrinol (Oxf). 2011 May. 74(5):593-8. [QxMD MEDLINE Link].

21. Mir O, Coriat R, Goldwasser F. Advances in pancreatic neuroendocrine tumor treatment. N Engl J Med. 2011 May 12. 364(19):1871; author reply 1873-4. [QxMD MEDLINE Link].

22. Virani S, Prajapati V, Devani A, Mahmood MN, Elliott JF. Octreotide-responsive necrolytic migratory erythema in a patient with pseudoglucagonoma syndrome. J Am Acad Dermatol. 2013 Feb. 68(2):e44-6. [QxMD MEDLINE Link].

23. Wei J, Song X, Liu X, Ji Z, Ranasinha N, Wu J, et al. Glucagonoma and Glucagonoma Syndrome: One Center's Experience of Six Cases. J Pancreat Cancer. 2018. 4 (1):11-16. [QxMD MEDLINE Link].

24. Poggi G, Villani L, Bernardo G. Multimodality treatment of unresectable hepatic metastases from pancreatic glucagonoma. Rare Tumors. 2009 Jul 22. 1(1):e6. [QxMD MEDLINE Link]. [Full Text].

25. Blackford S, Wright S, Roberts DL. Necrolytic migratory erythema without glucagonoma: the role of dietary essential fatty acids. Br J Dermatol. 1991 Nov. 125(5):460-2. [QxMD MEDLINE Link].

Ali Alikhan, MD Clinical Assistant Professor, Director of Clinical Trials, Residency Program Co-Director, Department of Dermatology, University of Cincinnati College of Medicine

Ali Alikhan, MD is a member of the following medical societies: American Academy of Dermatology, National Psoriasis Foundation, Cincinnati Dermatological Society, National Psoriasis Foundation, Ohio Dermatological Association

Disclosure: Nothing to disclose.

David F Butler, MD Former Section Chief of Dermatology, Central Texas Veterans Healthcare System; Professor of Dermatology, Texas A&M University College of Medicine; Founding Chair, Department of Dermatology, Scott and White Clinic

David F Butler, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, Association of Military Dermatologists, Phi Beta Kappa, Texas Dermatological Society

Disclosure: Nothing to disclose.

Warren R Heymann, MD Head, Division of Dermatology, Professor, Department of Internal Medicine, Rutgers New Jersey Medical School

Warren R Heymann, MD is a member of the following medical societies: American Academy of Dermatology, American Society of Dermatopathology, Society for Investigative Dermatology

Disclosure: Nothing to disclose.

William D James, MD Paul R Gross Professor of Dermatology, Vice-Chairman, Residency Program Director, Department of Dermatology, University of Pennsylvania School of Medicine

William D James, MD is a member of the following medical societies: American Academy of Dermatology, Society for Investigative Dermatology

Disclosure: Received income in an amount equal to or greater than $250 from: Elsevier; WebMD<br/>Served as a speaker for various universities, dermatology societies, and dermatology departments.

David P Fivenson, MD Associate Director, St Joseph Mercy Hospital Dermatology Program, Ann Arbor, Michigan

David P Fivenson, MD is a member of the following medical societies: American Academy of Dermatology, Michigan State Medical Society, Society for Investigative Dermatology, Photomedicine Society, Wound Healing Society, Michigan Dermatological Society, Medical Dermatology Society

Disclosure: Nothing to disclose.

Nathalie C Zeitouni, MDCM, FRCPC Chair of Dermatology, Associate Professor of Dermatology, Roswell Park Cancer Institute

Nathalie C Zeitouni, MDCM, FRCPC is a member of the following medical societies: American Academy of Cosmetic Surgery, American Academy of Dermatology, American College of Mohs Surgery, American Society for Dermatologic Surgery, Women's Dermatologic Society, Royal College of Physicians and Surgeons of Canada

Disclosure: Nothing to disclose.

Nishikant Harvey, MD Clinical Assistant Instructor, Department of Anesthesiology, SUNY at Buffalo Graduate Medical-Dental Consortium

Nishikant Harvey, MD is a member of the following medical societies: American Society of Anesthesiologists

Disclosure: Nothing to disclose.

Sara Flores, MD Resident Physician, Department of Dermatology, University of Cincinnati College of Medicine

Sara Flores, MD is a member of the following medical societies: American Academy of Dermatology, American Medical Association, American Society for Dermatologic Surgery, Cincinnati Dermatological Society, Ohio Dermatological Association

Disclosure: Nothing to disclose.

• Print this section
• Print the entire contents of
• Print the entire contents of article